The US Food and Drug Administration (FDA) has approved Klygefa (gefurulimab) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.
gMG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. It mostly develops in adults but children can also develop this rare condition. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. The condition results from a defect in the transmission of nerve impulses to muscles usually due to the presence of antibodies against the acetylcholine receptor. The exact reason this occurs is not known.
Gefurulimab is the first and only dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration via autoinjector. The approval is based on positive results from the pivotal PREVAIL phase 3 clinical trial, published in JAMA Neurology.
Results from the trial showed that gefurulimab met its primary endpoint, demonstrating improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo. In addition to the week 26 prespecified results, clinical improvement was observed as early as week one.
Gefurulimab was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG. The percentage of participants with treatment emergent adverse events (TEAEs) was similar between those who received gefurulimab and placebo, and most TEAEs observed were mild to moderate in severity. The most common TEAEs seen in those receiving gefurulimab were injection site reactions (12%), back pain (8%) and vomiting (5%).
For more information, visit https://www.astrazeneca.com/media-centre/press-releases/2026/klygefa-gefurulimab-approved-in-the-US.html
To learn more about gMG and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/
